Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study
- PMID: 22429255
- PMCID: PMC3741097
- DOI: 10.1037/a0027379
Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study
Abstract
A behavioral economic approach to understanding the relative value of alcohol may be useful for advancing medication development for alcoholism. Naltrexone is a heavily researched and moderately effective treatment for alcohol dependence making it a good candidate for a proof-of-concept study of behavioral economics and alcoholism pharmacotherapy. This study examines naltrexone efficacy and pharmacogenetics in terms of the relative value of alcohol, assessed via demand curve analysis. Participants were 35 heavy drinking (AUDIT ≥8) Asian Americans. A within-subjects cross-over medication design was used along with an intravenous alcohol challenge completed after 4 days of both naltrexone and placebo. At baseline and BrAC = 0.06g/dl, participants completed an Alcohol Purchase Task, which assessed estimated alcohol consumption along escalating prices. Behavioral economic demand curve analysis yielded measures of intensity, elasticity, maximum expenditure (O(max)), proportionate price insensitivity (P(max)) and breakpoint. Compared to placebo, naltrexone significantly reduced intensity, O(max) and breakpoint. There were also trend-level medication effects on P(max). BrAC was associated with increases in P(max) and breakpoint. A significant naltrexone × OPRM1 genotype interaction was observed for intensity of demand. The present study extends the literature on naltrexone's mechanisms through the application of a novel behavioral economic paradigm. These results indicate that naltrexone reduces several indices of demand for alcohol. This preliminary report provides further evidence for the effectiveness of naltrexone and supports the utility of a behavioral economic approach to alcoholism pharmacotherapy development.
Conflict of interest statement
None of the authors have any conflicts of interest to disclose.
Figures




Similar articles
-
Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.Arch Gen Psychiatry. 2007 Sep;64(9):1069-77. doi: 10.1001/archpsyc.64.9.1069. Arch Gen Psychiatry. 2007. PMID: 17768272 Clinical Trial.
-
Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.Neuropsychopharmacology. 2012 Jan;37(2):445-55. doi: 10.1038/npp.2011.192. Epub 2011 Sep 7. Neuropsychopharmacology. 2012. PMID: 21900886 Free PMC article. Clinical Trial.
-
Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.Addict Biol. 2013 Jan;18(1):193-201. doi: 10.1111/j.1369-1600.2012.00471.x. Epub 2012 Jul 11. Addict Biol. 2013. PMID: 22784013 Free PMC article. Clinical Trial.
-
The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.J Clin Psychopharmacol. 2006 Dec;26(6):610-25. doi: 10.1097/01.jcp.0000245566.52401.20. J Clin Psychopharmacol. 2006. PMID: 17110818 Review.
-
Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.CNS Neurol Disord Drug Targets. 2010 Mar;9(1):13-22. doi: 10.2174/187152710790966704. CNS Neurol Disord Drug Targets. 2010. PMID: 20201811 Review.
Cited by
-
A dual process perspective on advances in cognitive science and alcohol use disorder.Clin Psychol Rev. 2019 Apr;69:83-96. doi: 10.1016/j.cpr.2018.04.002. Epub 2018 Apr 11. Clin Psychol Rev. 2019. PMID: 29680185 Free PMC article. Review.
-
Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity.Am J Addict. 2017 Aug;26(5):516-525. doi: 10.1111/ajad.12463. Epub 2016 Nov 4. Am J Addict. 2017. PMID: 28134463 Free PMC article. Review.
-
Comparing exponential and exponentiated models of drug demand in cocaine users.Exp Clin Psychopharmacol. 2016 Dec;24(6):447-455. doi: 10.1037/pha0000096. Exp Clin Psychopharmacol. 2016. PMID: 27929347 Free PMC article.
-
Alcohol demand assessed daily as a predictor of same day drinking.Psychol Addict Behav. 2023 Feb;37(1):114-120. doi: 10.1037/adb0000890. Epub 2022 Dec 1. Psychol Addict Behav. 2023. PMID: 36455005 Free PMC article.
-
Understanding the effects of stress and alcohol cues on motivation for alcohol via behavioral economics.Alcohol Clin Exp Res. 2014 Jun;38(6):1780-9. doi: 10.1111/acer.12423. Epub 2014 May 30. Alcohol Clin Exp Res. 2014. PMID: 24890323 Free PMC article.
References
-
- Allen JP, Litten RZ, Fertig JB, Babor T. A review of research on the Alcohol Use Disorders Identification Test (AUDIT) Alcohol Clin Exp Res. 1997;21(4):613–619. - PubMed
-
- Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl) 2004;173(1–2):32–40. - PubMed
-
- Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156(11):1758–1764. - PubMed
-
- Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–2017. - PubMed
-
- Anton RF, Oroszi G, O’Malley S, Couper D, Swift R, Pettinati H, Goldman D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65(2):135–144. - PMC - PubMed